Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Acorda Therapeutics Inc (NASDAQ: ACOR) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Acorda Therapeutics Inc (NASDAQ: ACOR)  concerning whether a series of statements by Acorda Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On August 29, 2017, Acorda Therapeutics revealed that it had received a Refusal to File letter from the U.S. Food and Drug Administration ("FDA"), informing the Company that its New Drug Application for INBRIJA (CVT-301) "was not sufficiently complete to permit a substantive review." The FDA cited two specific issues: the date the manufacturing site would be ready for inspection; and a question regarding the submission of the drug master production record. Also, the FDA requested further information at resubmission, which did not form the basis for the Refusal to File.

On this news, NASDAQ: ACOR dropped $6.25 per share, or 24.32%, to close at $19.45 on August 29, 2017.

Based in Ardsley, New York, and founded in 1995 Acorda Therapeutics Inc is a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States.

If you purchased shares of Acorda Therapeutics Inc (NASDAQ:ACOR) on or before August 29, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185